Quetiapine and rivastigmine for agitation in Alzheimer’s disease

被引：1
|
作者：
Raymond L. Ownby
机构：
来源：
Current Psychiatry Reports | 2006年 / 8卷 / 1期
关键词：
Cognitive Decline; Cholinesterase; Quetiapine; Rofecoxib; Rivastigmine;
D O I：
10.1007/s11920-006-0075-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：10 / 10
相关论文
共 50 条
  • [1] Quetiapine in the treatment of agitation in patients with Alzheimer's disease
    Zhong, K
    Tariot, P
    Minkwitz, M
    Devine, N
    Mintzer, J
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 325 - 326
  • [2] The Effect of Adding Mirtazapine to Quetiapine on Reducing Agitation in Patients with Alzheimer's Disease
    Sayadnasiri, Mohammad
    Darvishskandari, Sahar
    Latifian, Maryam
    Islam, Sheikh Mohammed Shariful
    [J]. JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2024, 8 (01) : 143 - 150
  • [3] Rivastigmine for Alzheimer's disease
    Birks, Jacqueline S.
    Chong, Lee Yee
    Evans, John Grimley
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [4] Rivastigmine for Alzheimer's disease
    Birks, Jacqueline
    Evans, John Grimley
    Iakovidou, Vasso
    Tsolaki, Magda
    Holt, Francesca E.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [5] Rivastigmine for Alzheimer's disease
    Birks, Jacqueline S.
    Evans, John Grimley
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (04):
  • [6] Rivastigmine in the treatment of Alzheimer's disease
    Deleu, D
    [J]. EUROPEAN NEUROLOGY, 2001, 46 (02) : 111 - 111
  • [7] Evaluation of rivastigmine in Alzheimer's disease
    Nguyen, Kevin
    Hoffman, Heidi
    Chakkamparambil, Binu
    Grossberg, George T.
    [J]. NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 35 - 48
  • [8] Rivastigmine in the pharmacotherapy of Alzheimer's disease
    Volz, HP
    Maurer, I
    [J]. PSYCHOPHARMAKOTHERAPIE, 2001, 8 (03): : 104 - 110
  • [9] Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
    Ballard, C
    Margallo-Lana, M
    Juszczak, E
    Douglas, S
    Swann, A
    Thomas, A
    O'Brien, J
    Everratt, A
    Sadler, S
    Maddison, C
    Lee, L
    Bannister, C
    Elvish, R
    Jacoby, R
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7496): : 874 - 877
  • [10] The impact of rivastigmine (Exelon) on the usage of atypical neuroleptics in the treatment of agitation in patients with Alzheimer's disease (AD).
    Lee, PP
    Shua-Haim, JR
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S144 - S145
12345